Back to News
Market Impact: 0.22
MiniMed Group Consensus Price Target Increased by 20.43% to $26.24
Source: Nasdaq
Analyst EstimatesHealthcare & Biotech
MiniMed Group's aggregate one-year analyst price target was raised 20.43% to $26.24 per share as of September 15, 2026, from $21.79 on August 25. The upward revision signals improved analyst expectations for the medical-technology company, though the article provides no underlying earnings, operational, or guidance catalyst.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.32
Ticker Sentiment
MMED0.42
More News
- Tech giants need legacy businesses to keep growing as they pour trillions into the AI buildout
- Anthropic's IPO push includes a big bet on life sciences
- UnitedHealth is finally getting its act together. I'm buying into the turnaround
- Illumina CEO on Q3 Results and Business Outlook
- Swiss Firms Plan Investment Boost in China Drug, Finance Sectors
- Bernstein SocGen raises Eli Lilly stock price target on strong Q3 beat